Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 14/20 | 0.72 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.66 |
| ▸ | ULK1 | O75385 | 6/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503429 | 0.98 | PTK2B (0.72) | PTK2BPTK2ULK1SYKAURKA | |
| SCHEMBL3156242 | 0.89 | PTK2B (0.70) | PTK2BPTK2ULK1SYKAURKA | |
| SCHEMBL3154293 | 0.88 | PTK2B (0.77) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3164199 | 0.87 | PTK2B (0.80) | PTK2BPTK2ULK1SYK | |
| SCHEMBL3150037 | 0.86 | PTK2B (0.81) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL6211949 | 0.86 | SYK (0.57) | PTK2BPTK2ULK1SYK | |
| SCHEMBL3156106 | 0.86 | PTK2B (0.79) | PTK2BPTK2ULK1SYK | |
| SCHEMBL3155499 | 0.86 | PTK2B (0.79) | PTK2BPTK2ULK1SYK | |
| SCHEMBL3160125 | 0.85 | PTK2B (0.83) | PTK2BPTK2ULK1SYK | |
| SCHEMBL3154958 | 0.85 | PTK2B (0.81) | PTK2BPTK2ULK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625121-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-07-31 | — | — | US | claimed |
| US-20060281774-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-12-14 | — | — | US | claimed |
| US-7109335-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | claimed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | claimed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | claimed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-01-13 | — | — | US | claimed |
| US-7741336-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7674796-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1625121-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20080300234-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-07-31 | — | — | US | disclosed |
| US-7351712-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060281774-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-12-14 | — | — | US | disclosed |
| US-7109335-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | disclosed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20080300234-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20060281774-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.